ArticleAlzheimer's research & therapy2026
Intranasal administration of neural stem cell-derived extracellular vesicles prevents cognitive decline in both male and female 3×Tg-AD mice by dampening neuroinflammation and epigenetically regulating amyloid β metabolism.
Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAlzheimer’s disease (AD) is the leading cause of dementia in the elderly and poses a significant socioeconomic burden due to its progressive nature and lack of effective treatments. Recent studies suggest that neural stem cell-derived extracellular vesicles (NSC-EV) hold therapeutic potential against AD by delivering bioactive molecules that counteract neuroinflammation, oxidative stress, and protein dysregulation.
methodsNSC-EV were intranasally administered to both male and female 3×Tg-AD mice from three to twelve months of age and cognitive function were evaluated at multiple time points. Moreover, neuroinflammation and amyloid-β (Aβ) metabolism markers were studied at 9 months of age.
resultsIntranasal administration of NSC-EV delayed cognitive decline, reduced hippocampal neuroinflammation, and decreased Aβ accumulation in both male and female 3×Tg-AD mice. These functional effects were accompanied by the downregulation of STAT5 expression, which is a mediator of neuroinflammatory signaling, and the upregulation of neuroprotective transcription factor NRF2. Moreover, the changes in STAT5 and NRF2 expression caused the epigenetic inhibition of pro-amyloidogenic beta secretase BACE1 transcription and the enhanced expression of IDE, which is the main enzyme involved in Aβ clearance. These events were accompanied by the reduction of Aβ levels.
conclusionsOur findings provide new insights into the molecular mechanisms by which NSC-EV modulate AD pathology and support their potential as a regenerative therapy for neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.